Dr. Hyo-Soo Kim, of Seoul National University Hospital, discusses the results of the HOST-EXAM trial with Dr. Ron Waksman. The study, presented as a late-breaking trial at ACC.21 Virtual, showed that clopidogrel monotherapy in the chronic maintenance period following percutaneous coronary intervention and 6 to 18 months of dual antiplatelet therapy reduced cardiovascular risk by around 27% compared to aspirin monotherapy.